CG Oncology, Inc. (CGON) AI Stock Analysis

• Market Cap: $3.20B
• Dividend Yield: N/A
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.75
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 113
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.54
• Shares Outstanding: 76,247,580
• 10 Day Avg. Volume: 976,608
• 30 Day Avg. Volume: 1,092,109
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.41
• Enterprise Value/Revenue: 2.40K
• Enterprise Value/Gross Profit: 3.35K
• Enterprise Value/Ebitda: -8.41
• 1Y Price Target: $70.00
• Price Target Upside: 66.75% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13

• Rating: 56 Neutral
• Price Target: $44.00 ▲(4.81% Upside)

CG Oncology, Inc. scores moderately due to its strong technical momentum, which is offset by financial challenges and valuation concerns. The company's reliance on external funding and lack of revenue are significant risks, while positive market momentum provides some optimism.

Positive Factors

Strong Equity Position

A strong equity position indicates financial stability and resilience, providing a buffer against operational challenges and market fluctuations.

Cash Reserves

High cash reserves offer financial flexibility, allowing the company to invest in R&D and withstand periods of cash burn typical in biotech.

Innovative Therapies

Focus on innovative cancer therapies positions CGON to potentially capture significant market share in a growing sector, driving long-term growth.

Negative Factors

Reliance on External Funding

Dependence on external funding can lead to financial instability if market conditions change, affecting the company's ability to sustain operations.

No Revenue

Lack of revenue generation highlights the challenge of monetizing biotech developments, which may impact long-term financial viability.

Operational Inefficiencies

Ongoing operational inefficiencies suggest potential barriers in scaling and commercializing products, impacting profitability and growth.

CG Oncology, Inc. Business Overview & Revenue Model

Company Description

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

How the Company Makes Money

CG Oncology generates revenue primarily through the development and commercialization of its cancer therapies. The company may receive funding through partnerships and collaborations with larger pharmaceutical firms, which often involve milestone payments and royalties on future sales of approved products. Additionally, CGON may obtain revenue from government grants or research funding aimed at advancing its clinical trials. As the company progresses through the stages of drug development, it has the potential to generate significant earnings from product sales once its therapies are approved by regulatory bodies and launched into the market.

CG Oncology, Inc. Financial Statement Overview

Summary

CG Oncology, Inc. is facing financial challenges typical of early-stage biotechnology firms, with no current revenue and significant operating losses. The strong equity position and cash reserves provide some stability, but the reliance on external funding indicates potential risks if capital markets shift. The company’s focus should be on achieving revenue growth and improving operational efficiencies to sustain long-term viability.

Income Statement

CG Oncology, Inc. reported zero revenue in the latest year, indicating challenges in generating income. The company has experienced consistent losses with deteriorating EBIT and EBITDA margins, reflecting operational inefficiencies and potential barriers in monetizing its biotechnology developments.

Balance Sheet

The company's strong equity base relative to total assets, demonstrated by a high equity ratio, provides a solid financial foundation. However, the minimal debt levels and high cash reserves suggest limited leverage but also an underutilization of potential financing for growth.

Cash Flow

The negative free cash flow and significant negative operating cash flow highlight ongoing cash burn issues. Despite substantial financing inflows, the company is heavily reliant on external funding for operations, which could pose risks if such funding diminishes.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	551.00K	1.14M	204.00K	191.00K	10.36M
Gross Profit	395.00K	1.14M	204.00K	176.00K	10.35M
EBITDA	-157.24M	-114.63M	-55.43M	-35.23M	-12.38M
Net Income	-86.66M	-88.04M	-48.61M	-35.44M	-12.84M
Balance Sheet
Total Assets	701.45M	754.80M	199.30M	147.75M	58.69M
Cash, Cash Equivalents and Short-Term Investments	661.05M	742.00M	187.67M	143.48M	53.61M
Total Debt	994.00K	238.00K	461.00K	15.94M	15.13M
Total Liabilities	31.09M	21.42M	14.51M	22.57M	18.44M
Stockholders Equity	670.36M	733.38M	184.79M	125.18M	40.25M
Cash Flow
Free Cash Flow	-94.06M	-78.95M	-45.68M	-29.82M	-13.75M
Operating Cash Flow	-93.82M	-78.71M	-45.68M	-29.80M	-13.65M
Investing Cash Flow	-142.45M	-300.76M	-121.19M	-55.35M	-97.00K
Financing Cash Flow	225.74M	628.28M	87.00M	119.69M	15.45M

CG Oncology, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 41.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGON, the sentiment is Positive. The current price of 41.98 is above the 20-day moving average (MA) of 41.17, above the 50-day MA of 35.11, and above the 200-day MA of 28.30, indicating a bullish trend. The MACD of 2.04 indicates Positive momentum. The RSI at 59.54 is Neutral, neither overbought nor oversold. The STOCH value of 34.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CGON.

CG Oncology, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CGON	56 Neutral	$3.20B	―	-20.95%	―	―	―
IDYA	56 Neutral	$2.56B	―	-35.09%	―	-41.48%	-73.55%
ARQT	54 Neutral	$2.47B	―	-57.33%	―	99.50%	65.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BEAM	51 Neutral	$3.02B	―	-41.94%	―	-82.90%	-155.64%
IRON	43 Neutral	$3.00B	―	-26.36%	―	―	-22.19%
COGT	37 Underperform	$2.07B	-6.12	-107.55%	―	―	2.25%

CG Oncology, Inc. Corporate Events

CG Oncology Highlights Drug Potential at Healthcare Conference

CG Oncology, Inc. presented an updated corporate presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference on September 9, 2025, highlighting the potential of their investigational drug, cretostimogene grenadenorepvec, in treating bladder cancer. The presentation emphasized promising clinical trial results, including high response rates and a favorable safety profile, positioning the company to capitalize on a multi-billion dollar market opportunity in non-muscle invasive bladder cancer (NMIBC).

The most recent analyst rating on (CGON) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.

CG Oncology Announces Promising Phase 3 Trial Results

On September 5, 2025, CG Oncology announced updated data from its Phase 3 BOND-003 Cohort C trial, showing a 24-month complete response rate of 41.8% for cretostimogene monotherapy in high-risk non-muscle invasive bladder cancer patients unresponsive to BCG treatment. The trial demonstrated strong durability and tolerability, with no severe treatment-related adverse events reported, and 96.6% of patients were free from progression to muscle invasive disease at 24 months. The company plans to submit a Biologics License Application for cretostimogene in the fourth quarter of 2025, positioning it as a potential breakthrough treatment in this patient population.

The most recent analyst rating on (CGON) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.

CG Oncology’s Q2 2025: Clinical Advances and Legal Wins

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing innovative bladder-sparing therapeutics for bladder cancer patients.